Cannabis Israeli medical cannabis co Therapix lists on Nasdaq

Therapix Biosciences, which is developing treatments for Alzheimer's and Tourette syndrome, raised $12 million.

Philip Serlin  photo: PR BiolineRx buys UK co Agalimmune

BiolineRx is paying $6 million upfront for Agalimmune, which has developed a new immunotherapy solution for treating cancer.

Teva Photo: Tamar Matsafi Teva fires dozens in Israel

Many more employees will be let go in Israel and worldwide as the pharmaceutical company implements a new streamlining plan.

Schneider Children's Hospital Photo: Eyal Yizhar Schneider lands $7m artificial pancreas grant

A trial of an artificial pancreas with 100 patients will be conducted at the Israeli children's hospital with a US NIH grant.

Eran Linder-Ganz Photo: Eyal Yizhar Orthopedics co Active Implants raises $40m

The company's leading product is an artificial meniscus implant.

Benny Landa Photo: Eyal Yizhar Landa: It'll be tough for Teva to find new CEO

Teva activist shareholder Benny Landa says Teva's board of directors should resign.

Biotech development, photo: Shutterstock FDA fast tracks Israeli co PolyPid

PolyPid is developing a localized delayed release antibiotic for treatment of bone infections.

Sanara Ventures Photo: Itzik Biran Teva-Philips Israel incubator selects 9 projects

Sanara Ventures CEO Assaf Barnea: Over the past year we checked out 750 potential projects and chose nine.

Dr. Michael Hayden Photo: Tamar Matsafi "Next 4 months most interesting in Teva's history"

Teva R&D chief Dr. Michael Hayden was referring to a series of Phase III clinical trial results and FDA approvals that are expected.

pharmaceuticals Intec Pharma raises $10m in private placement

The Israeli biopharma company has developed an oral drug delivery system to improve the efficacy and safety of drugs by utilizing an efficient gastric retention and release mechanism.

Yitzhak Peterburg S&P keeps negative outlook for Teva

S&P reiterated Teva's BBB rating, but downgraded its management and governance score.

Amit Goffer UPnRIDE Photo: Company website UPnRIDE lets wheelchair users stand and ride

Having set up ReWalk to help those paralyzed below the waist, Amit Goffer's new startup will also help those with upper body paralysis, including himself.

Prof. Yitzhak Haviv Photo: Amir Meiri "Sometimes saving lives justifies crony capitalism"

Bar-Ilan University biologist Prof. Izhak Haviv insists personalized medicine to cure cancer in affluent people will help all patients.

dentistry image: Shutterstock/ASAP Creative Israeli dental tech cos lead in implant innovations

Poalim Capital Markets: We want to help the Israel medical market mature into a global leader.

Erez Vigodman Photo: Eyal Yizhar Teva's outgoing CEO earned NIS 20m in 2016

Teva's five highest-paid executives earned an aggregate $25 million.

Teva Teva campus construction to continue despite cost

The Ra'anana campus will house Teva's headquarters, laboratories, and production facilities.

Erez Vigodman, Benny Landa Photos: Eyal Yizhar Landa: Teva needs CEO with pharma background

Activist shareholder Benny Landa thinks Teva should be split into generics and branded drugs companies.

Arie Belldegrun Photo: PR "Teva slow to prepare for life after Copaxone"

Kite Pharma CEO Arie Belldegrun, who resigned from Teva's board: Teva's pipeline provides sufficient infrastructure to make it a significant innovative player.

Erez Vigodman photo: Eyal Yitzhar Debt weighs on Teva

On top of all its other woes, the Israeli pharmaceutical giant has a net debt of $35 billion, higher than its $32 billion market cap.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2016